Table 2.

A summary of participants’ use of Prosdex: mean time (seconds); mean number of pages viewed; percentage of available pages viewed and percentage of videos/animations viewed among men in the low, intermediate, and high access groups

		Time		Access
Module/Section		Mean (SD)a Time in Seconds Spent in Module/ Section	Range	Total Number of Pages in Module/ Section	Mean Number (SD)b of Pages Viewed	Percent of Available Pages Viewed Among Men in Each Group
						Low Access (n = 37)	Intermediate Access (n = 18)	High Access (n = 27)
PROSDEX site		1191 (914)	75-3672	60	32 (21)	19	60	94
The PSA Test		412 (329)	0-1385	19	11 (6)	37	58	91
	Introduction	8 (19)	0-99	1	0.5 (0.5)	24	28	37
	What is the PSA test?	91 (66)	0-310	3	2 (1)	67	85	94
	PSA test results	132 (129)	0-772	5	3 (2)	45	68	92
	PSA controversies	103 (118)	0-420	6	3 (2)	28	44	93
	What is screening?	76 (87)	0-327	4	2 (2)	22	56	97
It’s Your Choice		218 (263)	0-996	19	9 (8)	5	51	97
	Introduction	13 (15)	0-77	1	1 (0.5)	54	83	93
	Making the best decisions	18 (49)	0 -394	2	1 (1)	4	58	94
	Knowing enough to choose	65 (85)	0-302	5	2 (2)	1	70	99
	Shared decision making	49 (70)	0-285	4	2 (2)	3	42	98
	Choices about the PSA test	44 (70)	0-341	4	2 (2)	2	32	99
	Screening in other countries	29 (42)	0-212	3	1 (1)	5	39	94
Prostate Cancer		428 (449)	0-1824	22	12 (9)	15	70	94
	Introduction	15 (14)	0-63	1	1 (0.5)	43	100	96
	The prostate	70 (68)	0-231	3	2 (1)	20	70	95
	Understanding the risks	60 (82)	0-503	4	2 (2)	12	76	100
	Detecting prostate cancer	114 (169)	0-733	5	3 (2)	17	63	91
	Treating prostate cancer	115 (180)	0-883	5	2 (2)	10	68	90
	Early treatment	50 (59)	0-228	4	2 (2)	12	65	94

^a based on 74 participants (8 outliers excluded)

^b based on 82 participants (8 outliers did not sufficiently distort usage data)